Clinical Trial Update: Axitinib and Nivolumab for the Treatment of Mucosal Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of axitinib and nivolumab for mucosal melanoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucosal Melanoma

Drugs mentioned

• Axitinib (Axitinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Mucosal Melanoma | Phase 2 | Status: RECRUITING